Search

Your search keyword '"American Society of Clinical Oncology"' showing total 14 results
Start Over Author "American Society of Clinical Oncology" Publisher amer soc clinical oncology
14 results on '"American Society of Clinical Oncology"'

1. Zoledronic acid (ZOL) treatment (Rx) of >= 2 years in patients (pts) with metastatic bone disease (MBD) or multiple myeloma (MM): Six-month results from the LOTUZ study

Author

UCL - Autre, Duck, L., Delforge, Michel, Doyan, C., Wildiers, H., MacDonald, K., Lechat, I., Abraham, Ivo, 45th Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Autre, Duck, L., Delforge, Michel, Doyan, C., Wildiers, H., MacDonald, K., Lechat, I., Abraham, Ivo, and 45th Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2009

2. Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicenter prospective phase II clinical study

Author

UCL - Autre, Hompes, D., D'Hoore, A., Van Cutsem, E., Ceelen, W., Peeters, Marie-Rose, Van der Speeten, K., Bertrand, C., Kerger, Joseph, Legendre, H., 45th Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Autre, Hompes, D., D'Hoore, A., Van Cutsem, E., Ceelen, W., Peeters, Marie-Rose, Van der Speeten, K., Bertrand, C., Kerger, Joseph, Legendre, H., and 45th Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2009

3. Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: A randomized trial from the GETTEC and GORTEC groups.

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/NOPS - Département de neurologie et de psychiatrie, Janot, F., Hamoir, Marc, de Raucourt, Dominique, Castaing, M., Bardet, E., Dolivet, G., Bensadoun, R., Marandas, P., Mamelle, G., Bourhis, J., 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Cliniques universitaires Saint-Luc, UCL - MD/NOPS - Département de neurologie et de psychiatrie, Janot, F., Hamoir, Marc, de Raucourt, Dominique, Castaing, M., Bardet, E., Dolivet, G., Bensadoun, R., Marandas, P., Mamelle, G., Bourhis, J., and 42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2006

4. A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC).

Author

UCL - Autre, Sculier, J., Lafitte, J., Lecomte, J., Alexopoulos, C.G., Van Cutsem, O., Giner, V., Efremidis, A., Scherpereel, A., Paesmans, M., Berghmans, T., 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Autre, Sculier, J., Lafitte, J., Lecomte, J., Alexopoulos, C.G., Van Cutsem, O., Giner, V., Efremidis, A., Scherpereel, A., Paesmans, M., Berghmans, T., and 42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2006

5. Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC).

Author

UCL, Siegel-Lakhai, WS, Rodenstein, Daniel, Beijnen, JH, Gianella-Borradori, A, Schellens, JHM, Talbot, DC, 41st Annual Meeting of the American-Society-of-Clinical-Oncology, UCL, Siegel-Lakhai, WS, Rodenstein, Daniel, Beijnen, JH, Gianella-Borradori, A, Schellens, JHM, Talbot, DC, and 41st Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2005

6. A phase IB, open-label, parallel design study of PTK787/ZK 222584 in combination with irinotecan in patients (Pts) with metastatic colorectal cancer (CRC) to investigate the interaction between the agents.

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Teipar, S, Humblet, Yves, Lin, E, Bono, P, Jalava, T, Kay, A, Masson, E, Laurent, D, Joensuu, H, Van Cutsem, E., 41st Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Teipar, S, Humblet, Yves, Lin, E, Bono, P, Jalava, T, Kay, A, Masson, E, Laurent, D, Joensuu, H, Van Cutsem, E., and 41st Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2005

7. An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC).

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Humblet, Yves, Peeters, Marie-Rose, Bleiberg, H., Stupp, R., Sessa, C., Roth, A, Nippgen, J, Nolting, A, Stuart, P, Giaccone, Giuseppe, 41st Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Humblet, Yves, Peeters, Marie-Rose, Bleiberg, H., Stupp, R., Sessa, C., Roth, A, Nippgen, J, Nolting, A, Stuart, P, Giaccone, Giuseppe, and 41st Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2005

8. Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study.

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/IEPR - Institut d'éducation physique et de réadaptation, UCL - MD/MINT - Département de médecine interne, Rubio, ED, Humblet, Yves, Tabernero, J., Van Cutsem, E., Cervantes, A., André, Thibaut, Soulie, P, Corretge, S, Kisker, O., de Gramont, A., 41st Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Cliniques universitaires Saint-Luc, UCL - MD/IEPR - Institut d'éducation physique et de réadaptation, UCL - MD/MINT - Département de médecine interne, Rubio, ED, Humblet, Yves, Tabernero, J., Van Cutsem, E., Cervantes, A., André, Thibaut, Soulie, P, Corretge, S, Kisker, O., de Gramont, A., and 41st Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2005

9. Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963.

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Levi, F, Humblet, Yves, Gorlia, Thierry, Tubiana, N, Smaaland, R, Canon, JL., Lentz, MA., Focan, C., Bjarnason, G, Giacchetti, S, 41st Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Levi, F, Humblet, Yves, Gorlia, Thierry, Tubiana, N, Smaaland, R, Canon, JL., Lentz, MA., Focan, C., Bjarnason, G, Giacchetti, S, and 41st Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2005

10. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An international multicenter study

Author

UCL - Autre, Efficace, Fabio, Therasse, Patrick, Piccart, Martine, Coens, Corneel, Van Steen, Kristel, Welnicka-Jaskiewicz, Marzena, Cufer, Tanja, Dyczka, Jaroslaw, Lichinitser, Michail, Shepherd, Lois, de Haes, Hanneke, Sprangers, Mirjam A., Bottomley, Andrew, 40th Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Autre, Efficace, Fabio, Therasse, Patrick, Piccart, Martine, Coens, Corneel, Van Steen, Kristel, Welnicka-Jaskiewicz, Marzena, Cufer, Tanja, Dyczka, Jaroslaw, Lichinitser, Michail, Shepherd, Lois, de Haes, Hanneke, Sprangers, Mirjam A., Bottomley, Andrew, and 40th Annual Meeting of the American-Society-of-Clinical-Oncology

Abstract

Purpose The purpose of this research was to evaluate whether baseline health-related quality of life (HRQOL) parameters are prognostic factors for survival in locally advanced breast cancer patients. Although the literature highlights the important role of HRQOL parameters in predicting survival in advanced metastatic disease, little evidence exists for earlier stages. Patients and Methods The overall sample consisted of 448 patients randomly assigned to receive cyclophosphamide, epirubicin, and fluorouracil versus epirubicin, cyclophosphamide, and granulocyte colony-stimulating factor. Patients were enrolled in 12 countries. HRQOL baseline scores were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30. The Cox proportional hazards regression model was used for both univariate and multivariate analyses of survival. In addition, a bootstrap resampling technique was used to assess the stability of the outcomes. Bootstrap results were then applied for model averaging purposes as a means to account for the observed model selection uncertainty. Results The final multivariate model retained inflammatory breast cancer (T4d) as the only factor predicting overall survival (OS) with a hazard ratio of 1.375 (95% CI, 1.027 to 1.840; P = .03). The presence of inflammatory breast cancer lowers the median survival time from 6.6 to 4.2 years (36% reduction). None of the preselected HRQOL variables were prognostic for OS or disease-free survival, in either the univariate or multivariate analysis. Conclusion Our findings suggest that baseline HBQOL parameters have no prognostic value in a nonmetastatic breast cancer population.

Published
2004

11. Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3NO prostate cancer (PC)? (EORTC 22911)

Author

UCL, Bolla, M., Van Poppel, H., Van Cangh, Paul, Vekemans, K., Rigatti, P, de Reijke, T., Verbaeys, A, Bosset, JF, Collette, Laurence, 40th Annual Meeting of the American-Society-of-Clinical-Oncology, UCL, Bolla, M., Van Poppel, H., Van Cangh, Paul, Vekemans, K., Rigatti, P, de Reijke, T., Verbaeys, A, Bosset, JF, Collette, Laurence, and 40th Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2004

12. Dose-limiting effects of neutropenic events in six European audits of adjuvant breast cancer chemotherapy.

Author

UCL - Autre, Szucs, TD, Leonard, R., Pettengell, R., Paridaens, Robert, Jackisch, C., Constenla, M., Bosly, André, Schwenkglenks, M., 40th Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Autre, Szucs, TD, Leonard, R., Pettengell, R., Paridaens, Robert, Jackisch, C., Constenla, M., Bosly, André, Schwenkglenks, M., and 40th Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2004

13. Peptide receptor radiotherapy (PRRT) with [Y-90-DOTA,Tyr3]octreotide: Toxicity and efficacy of 4-cycle and single-cycle regimens

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Valkema, R, Pauwels, Stanislas, Jamar, François, Kvols, LK, Barone, Raffaella, Lasher, J, Krenning, EP, 40th Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Valkema, R, Pauwels, Stanislas, Jamar, François, Kvols, LK, Barone, Raffaella, Lasher, J, Krenning, EP, and 40th Annual Meeting of the American-Society-of-Clinical-Oncology

Published
2004

14. Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials - Does HRQOL evaluation in prostate cancer research inform clinical decision making?

Author

UCL - Autre, Efficace, Fabio, Bottomley, Andrew, Osoba, David, Gotay, Carolyn, Flechtner, Henning, D'haese, Sven, Zurlo, Alfredo, 39th Annual Meeting of the American-Society-of-Clinical-Oncology, UCL - Autre, Efficace, Fabio, Bottomley, Andrew, Osoba, David, Gotay, Carolyn, Flechtner, Henning, D'haese, Sven, Zurlo, Alfredo, and 39th Annual Meeting of the American-Society-of-Clinical-Oncology

Abstract

Purpose : The aim of this study was to evaluate whether the inclusion of health-related quality of life (HRQOL), as a part of the trial design in a randomized controlled trial (RCT) setting, has supported clinical decision making for the planning of future medical treatments in prostate cancer. Materials and Methods: A minimum standard checklist for evaluating HRQOL outcomes in cancer clinical trials was devised to assess the quality of the HRQOL reporting and to classify the studies on the grounds of their robustness. It comprises 11 key HRQOL issues grouped into four broader sections: conceptual, measurement, methodology, and interpretation. Relevant studies were identified in a number of databases, including MEDLINE and the Cochrane Controlled Trials Register. Both their HRQOL and traditional clinical reported outcomes were systematically analyzed to evaluate their consistency and their relevance for supporting clinical decision making. Results: Although 54% of the identified studies did not show any differences in traditional clinical end points between treatment arms and 17% showed a difference in overall survival, 74% of the studies showed some difference in terms of HRQOL outcomes. One third of the RCTs provided a comprehensive picture of the whole treatment including HRQOL outcomes to support their conclusions. Conclusion: A minimum set of criteria for assessing the reported outcomes in cancer clinical trials is necessary to make informed decisions in clinical practice. Using a checklist developed for this study, it was found that HRQOL is a valuable source of information in RCTs of treatment in metastatic prostate cancer. (C) 2003 by American Society of Clinical Oncology.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results